Trial Profile
A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose, Safety Study of MYO-029 Administered to Adult Patients with Becker, Facioscapulohumeral and Limb-Girdle Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Stamulumab (Primary)
- Indications Duchenne muscular dystrophy; Facioscapulohumeral muscular dystrophy; Limb girdle muscular dystrophies
- Focus Adverse reactions
- Sponsors Pfizer
- 05 Sep 2019 New source identified and integrated: European Clinical Trials Database (EudraCT2004-000622-67).
- 30 May 2014 New trial record